Genfit Stock in 2026: Price, Biotech and Outlook

Genfit stock (ticker GNFT, Euronext Paris, ISIN FR0004163111) is the most exciting French biotech bet on the Paris market: as of October 23, 2026, the shares trade at around €8.67, a spectacular gain of 132.44% over one year — while the analyst consensus shows a median target of €19.23, a theoretical upside of 121.84%.

This setup — a share price that has doubled and a target that would double it again — sums up the nature of the case: a liver specialist whose business model is shifting. After years of losses, Iqirvo royalties are now offsetting pressure on cash, the MASH diagnostics business is targeting $1.5 billion in US sales, and losses per share are melting away: −€1.72 in 2025, −€0.03 expected in 2026, ahead of a first profit estimated for 2027. This guide covers the whole bet: price, pipeline, figures, risks and the buying decision.

Genfit Stock Price Today

Genfit is listed on Euronext Paris, in euros, in the small and mid cap segment — around €434 million. The stock is eligible for both the PEA and the PEA-PME, a rare double advantage for a biotech. Liquidity has improved markedly with the announcement of its upcoming inclusion in the SBF 120 and the CAC Mid 60: index funds and institutional investors will now have to hold the stock.

Recent figures: €8.67 on October 23, down 2.47% on the session and 4.20% over one month — a consolidation pause after a surge. The longer trajectory speaks for itself: +5.99% over six months, but above all +132.44% over one year, +186.14% over three years and +172.64% over five years.

The ten-year window, however, is a reminder of where the stock has come from: −52.51%. Genfit stock suffered one of the most brutal falls in European biotech after the failure of its major NASH trial — before rebuilding itself brick by brick. A negative ten-year record and a triple-digit one-year gain coexist: the hallmark of a turnaround story, not a quiet stock.

Against this backdrop, the consensus — five buys and one hold among six analysts, a median rating of 1.33 — keeps the median target at €19.23: more than double the share price. The mood is reminiscent of other biotech stocks covered on the site, where therapeutic potential and clinical risk compete for every line of the valuation.

Before you decide, also look at how Gilead Sciences stock is performing. You can also read our profile of Ipsen.

The Business: the Liver Biotech

Genfit was born in Lille from a rare specialization: liver biology. This strategic choice covers two complementary businesses. The first is therapeutic: developing treatments for liver diseases — first metabolic steatohepatitis, the well-known NASH now renamed MASH, then primary biliary cholangitis (PBC), a rare autoimmune disease that destroys the bile ducts.

The second business is diagnostics: non-invasive blood tests that make it possible to identify patients with liver disease without a biopsy. This is the area carrying the most quantified commercial ambition today: management is targeting $1.5 billion in sales in MASH diagnostics in the United States — a mass market, since fatty liver disease affects millions of people in Western countries.

The business model has two tiers, as with any biotech: a revenue tier — Iqirvo royalties and diagnostic test sales — that funds the business; and an options tier — the clinical pipeline, acquisitions and additional indications — on which the next steps in valuation depend. The difference from the recent past: the first tier is starting to genuinely carry the company.

Iqirvo: Turning a Failure Around

The Iqirvo story is one of scientific persistence. The molecule — elafibranor — initially targeted NASH, where its major Phase 3 trial ended in a resounding failure: the stock lost most of its value in a single session. Rather than abandon the molecule, the teams redirected it toward primary biliary cholangitis — where it demonstrated its efficacy, all the way to approval.

Marketed with industrial partner Ipsen — which is running the Phase IIIb ELSPIRE study in PBC patients — Iqirvo now generates royalties that, according to recent news on the stock, offset the pressure on cash. For a biotech, this shift is decisive: partner money arrives before market money, and each newly approved market widens the royalty base.

For shareholders, there are two takeaways. On the one hand, Iqirvo validates the group’s scientific platform and its ability to take programs all the way to approval — the rarest skill in the business. On the other, dependence on the partner calls for vigilance: the pace of launches, the expansion of indications and the financial terms of the partnership determine how strong the royalties will be.

Diagnostics: the Other Pillar of the Thesis

The diagnostics business is advancing on a separate front: recognition by the US healthcare system. The announcement of coverage and future reimbursement for a diagnostic product in the United States sent the stock soaring — because reimbursement turns a promising test into a prescribed healthcare product, built into care pathways.

This is the barrier that has just fallen, opening access to the mass market: the target of $1.5 billion in MASH diagnostics sales assumes prescription volumes on the scale of a silent epidemic — fatty liver disease, a consequence of obesity and diabetes, is spreading across all Western populations.

The logic of the case then comes full circle: diagnostics identify patients, prescriptions become widespread, and the data collected adds value to the platform. Recent technical analyses also note that “prices are still rising”, driven by this fundamental momentum — a rare alignment between the chart and the fundamentals.

Cash Runway and the Path to Profit

The question of financial survival, a classic for biotechs, has an unusual answer here: management has announced a cash runway extending beyond the end of 2028. In other words, more than two years of headroom without relying on the market — a comfort that changes the nature of the risk: the danger of urgent dilution recedes, and with it the classic scenario of a capital increase at the worst possible moment.

Consensus estimates map out the path: a loss per share of −€1.72 in 2025, narrowing to an expected −€0.03 in 2026 — almost break-even — followed by a first profit estimated at €0.17 per share in 2027. The estimated P/E for that pivotal year, close to 48, says it all: the market is already paying for future profitability, not current profitability.

This financial profile explains the stock’s recovery better than any sentimental argument: Iqirvo royalties and diagnostic sales arrive just in time to cover costs, while the recent acquisition in ACLF — acute-on-chronic liver failure — broadens the portfolio without draining reserves.

History: from the NASH Failure to a Revival

Genfit was founded in the late 1990s within Lille’s scientific ecosystem, around a conviction: liver diseases would become one of the century’s major public health issues. The company became known to the wider investing public through a defining episode: the major clinical trial of its NASH candidate — non-alcoholic steatohepatitis — which ended in a Phase 3 failure.

The market showed no mercy: the stock lost most of its value in a single session, and the decade that followed still leaves its mark in the ten-year record of −52.51%. But this failure paradoxically shaped the revival: the molecule was redirected toward primary biliary cholangitis, where it found its indication; the platform diversified into diagnostics; and the company culture kept the memory of clinical risk — hence a portfolio now spread across treatments, tests and partnerships.

The stock’s recent trajectory — +186% over three years, +132% over one year and an announced inclusion in the SBF 120 — rewards this rebuilding. For shareholders, the story teaches the sector’s rule: in biotech, science decides and the stock market follows. Every step in the revival of Genfit stock is tied to a dated medical event — approval, reimbursement, acquisition — never to a disembodied narrative.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

How to Read a Biotech’s Milestones

Following Genfit means reading its reports like a clinician, not an accountant. Three families of milestones matter. First, regulatory milestones: extensions of Iqirvo’s approval and US reimbursement decisions for the tests — these are what open or close markets. Second, clinical milestones: study results — notably ELSPIRE in PBC — that confirm or weaken the scientific foundation. Finally, financial milestones: cash, royalties and break-even.

What makes the Genfit case special is that these three families are now connected: royalties fund the pipeline, the pipeline broadens the reimbursement base, and the cash runway secured beyond the end of 2028 gives management time to see the strategy through. This virtuous circle, rare at this stage in the sector, is the central argument of the analysts rating it a buy — and the first thing to check in every report.

Key Figures and Analyst Consensus

The dashboard as of October 23, 2026: share price €8.67, market capitalization €434 million, no dividend — normal for a biotech nearing break-even — and a strongly skewed breakdown of recommendations: five buys, zero outperform, one hold and no sells, among six analysts.

ISINFR0004163111
Exchange and tickerParis — GNFT.PA
SectorHealthcare
Genfit S.A.GNFT.PA · Paris
10,64 €-0,56 %
Clôture précédente10,70 €
Plus haut du jour10,78 €
Plus bas du jour10,42 €
Plus haut 52 semaines15,48 €
Plus bas 52 semaines3,66 €
Volume135 177
Capitalisation533 M
Rendement du dividende0,00 %
Objectif moyen des analystes21,64 €
Mis à jour le 2026-11-19 16:45:34 · Source : Yahoo · Données indicatives, ne constituent pas un conseil en investissement.

Yahoo Finance — data checked on 10/23/2026: price and fundamentals. Market data is indicative only and does not constitute investment advice.

The median rating of 1.33 places the stock between a strong buy and a moderate buy. The median target of €19.23 implies upside of 121.84%; three months ago, the breakdown was even more clear-cut — six buys out of six. The slight decline in the number of buy ratings after the share price doubled reflects analysts’ natural caution with a stock that has already delivered a lot.

Oddo BHF, in particular, recently reaffirmed its positive stance on the stock. From a portfolio perspective, Genfit stock fits alongside the other healthcare holdings covered on the site: the pure biotech bet with Valneva stock, the dividend strength of a big pharma group with Sanofi stock — and liver specialization with Genfit stock: three very different risk profiles within the same sector.

How to Buy Genfit Stock

You can buy it on Euronext Paris through a brokerage account or a PEA — PEA-PME eligibility also opens the door to the plan dedicated to small businesses. Our guide on how to invest in the stock market and our comparison of reliable brokers explain the mechanics. For a stock of this size, limit orders remain the rule: spreads can be wide at the open and around announcements.

The calendar matters more than timing: US reimbursement announcements, study results — notably ELSPIRE — updates on SBF 120 inclusion and periodic cash updates are the events that move the stock. Building the position in tranches, while keeping reserves for consolidations, is the method best suited to the stock’s structural volatility.

The Risks of Investing in Genfit

Clinical and regulatory risk remains the backbone of the whole case: a disappointing study, a reimbursement delay or an unfavorable agency decision — and the stock can give back in weeks what it took a year to gain. The NASH episode showed that such shocks happen.

Commercial execution risk: the $1.5 billion diagnostics target is an ambition, not an accounting reality; achieving it requires agreements, a sales force and adoption by doctors — a path full of hurdles. Finally, valuation risk: after a 132% gain in a year, part of the success is priced in, and the 2027 P/E leaves no room for disappointment.

Added to this is a structural risk: only six analysts cover the stock — thin coverage that can amplify moves in both directions. And dependence on Iqirvo’s commercial partner, whose launch decisions are partly outside the group’s control, needs to be monitored report after report.

Our Take: Should You Buy Genfit Stock in 2026?

The bull case: a liver specialist whose model has finally been unlocked — rising Iqirvo royalties, diagnostics reimbursed in the United States, a cash runway beyond the end of 2028 and losses shrinking toward the profit estimated for 2027 — backed by a consensus of five buys out of six and a target more than double the share price.

The cautious case: the stock has already doubled, the valuation assumes flawless execution of the diagnostics plan, and the sector’s history shows that biotechs severely punish missteps. Our conclusion: Genfit stock is a higher-quality biomedical bet — diversified, funded and approaching break-even — to be treated as such: a position sized to absorb a regulatory shock, built in tranches, with close monitoring of milestones. It is not an income stock; it is an industrial option on liver medicine.

Genfit Stock FAQ

What is the Genfit stock price today?

As of October 23, 2026, Genfit stock trades at around €8.67 on Euronext Paris — down 2.47% on the session and 4.20% over one month, but up 132.44% over one year and 172.64% over five years.

What exactly does Genfit do?

Genfit is a French biotech specializing in liver diseases: it develops treatments — including Iqirvo, approved for primary biliary cholangitis — and non-invasive blood diagnostic tests, notably for MASH, fatty liver disease.

What is the analysts’ price target?

The median consensus target stands at €19.23, an upside of 121.84% above the October 23, 2026 price — with five buys, one hold and no sells among six analysts, and a median rating of 1.33.

Is Genfit profitable?

Not yet: the loss per share was €1.72 in 2025, narrowing to an expected −€0.03 in 2026 — almost break-even — ahead of a first profit estimated at €0.17 per share in 2027. Iqirvo royalties and diagnostic sales are driving this transition.

Is Genfit’s cash position solid?

Yes, it is one of the strengths of the case: management has announced a cash runway beyond the end of 2028, and recent news confirms that Iqirvo royalties are offsetting the pressure on cash — reducing the risk of urgent dilution that threatens so many comparable biotechs.

Is Genfit stock PEA-eligible?

Yes: the stock is eligible for the PEA and the PEA-PME, and its announced inclusion in the SBF 120 and the CAC Mid 60 increases its visibility with institutional investors.

Should you buy Genfit stock, and is it listed on the Nasdaq?

On buying: this guide sets out both sides — a pipeline of liver treatments with royalties starting to flow and break-even estimated around 2027, against the classic risks of biotech; the consensus, mostly buy-rated with a target detailed in this guide, is revised at each clinical milestone. On the listing: the benchmark line is Euronext Paris (GNFT), which is PEA-eligible — the group also has ADSs traded in the United States, representing the same company; for a French investor, the Paris route remains the simplest and most tax-efficient.

Conclusion: an Option on Liver Medicine

In 2026, Genfit stock offers what the market increasingly demands from biotechs: a credible path to profitability, backed by real revenue — royalties from an approved treatment and reimbursed diagnostics — rather than promises alone. The stock doubling in a year, the €19.23 consensus target and the cash runway beyond 2028 point to a case that has changed in nature.

The sector’s discipline still applies: regulatory milestones will keep coming, and each one can reshape the share price curve in a single session. For investors who accept this volatility, with a properly sized position and rigorous monitoring of reports, Genfit stock deserves its place in the innovation portion of a diversified portfolio — a French biomedical bet, finally backed by real cash flows and fresh institutional visibility.

Suivez-nous sur Telegram